Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON47767
NL-OMON47767
Completed
Phase 4

The clinical prognostic value of amyloid imaging with [18F]AV-45 in a subjects with subjective complaints - Clinical prognostic value [18F]AV-45

Vrije Universiteit Medisch Centrum0 sites280 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAlzheimer's Diseasedementia of the Alzheimer type1002930510012272

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Alzheimer's Disease
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
280
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- age \>45
  • •\- Written informed consent
  • •\- Weight \>50 kg , \- Able to tolerate 70\-minute scanning
  • •\- No objective cognitive impairment (i.e. no diagnosis of dementia, mild cognitive impairment, psychiatric or neurological disorder explaining cognitive complaints).
  • •\- MMSE \>\<\= 18

Exclusion Criteria

  • •Patients who
  • •1\. Have a current a major psychiatric disorder, such as psychosis, schizophrenia, severe personality disorder or depression with vital signs, abuse of alcohol or other substances. Or patients who have a neurological disorder, such as Parkinson's disease, symptomatic stroke, mental retardation.
  • •2\. Are women of childbearing potential who are not surgically sterile, not refraining
  • •from sexual activity or not using reliable methods of contraception. Women of
  • •childbearing potential must not be pregnant (negative urine \*\-hCG at the time of
  • •screening and negative urine \*\-hCG on the day of imaging) or breast feeding at
  • •screening. Women must avoid becoming pregnant, and must agree to refrain from
  • •sexual activity or to use reliable contraceptive methods such as prescribed birth
  • •control or IUD for 24 hours following administration of florbetapir (18F);
  • •3\. Have a relevant history of severe drug allergy or hypersensitivity (relevant severe

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Determine the value of the compound [18F]-AV45, which is usable for visualization of the build-up of the amyloid protein in brains of memory clinic patients, in making a diagnosis in patients of the memory outpatient clinic.The total number of inclusion in this study is 170 subjects140 patients (including Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI), patients with subjective memory complaints (SMC), patients with other neurodegenerative diseases and 30 cognitively normal volunteers.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2012-001599-12-NLVU University Medical Center (VUmc)170
Active, not recruiting
Not Applicable
Amyloid Imaging in Alzheimer´s diseaseImaging amyloid plaques in patients with probable Alzheimer´s disease using [11C]PIB and [18F]FDDNP PET
EUCTR2007-000148-28-ATDepartment of Neurology, Medical University of Vienna
Completed
Not Applicable
Studies on the amyloid PET imaging in patients with dementiapatients with dementia
JPRN-UMIN000010767Mie University Graduate School of Medicine30
Recruiting
Not Applicable
The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease
JPRN-jRCTs051180214Itoh Yoshiaki100
Not yet recruiting
Not Applicable
Serum Amyloid A as a prognostic marker for disease severity and mortality in COVID-19
NL-OMON20323Board of Directors Franciscus Gasthuis & Vlietland350